Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> JAK/STAT Signaling

JAK/STAT Signaling

Targets for  JAK/STAT Signaling

Products for  JAK/STAT Signaling

  1. Cat.No. Product Name Information
  2. GC14170 Nifuroxazide STAT inhibitor Nifuroxazide Chemical Structure
  3. GC48839 Nifuroxazide-d4 An internal standard for the quantification of nifuroxazide Nifuroxazide-d4 Chemical Structure
  4. GC33131 NRC-2694 NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 Chemical Structure
  5. GC14653 NSC 74859 Stat3 inhibitor NSC 74859 Chemical Structure
  6. GC69594 NSC-370284

    NSC-370284 is a selective inhibitor of both 10-11 translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). It significantly inhibits TET1 expression levels by targeting STAT3/5.

     NSC-370284 Chemical Structure
  7. GC14103 NSC228155 EGFR activator NSC228155 Chemical Structure
  8. GC69596 NSC689857

    NSC689857 is an effective inhibitor of EGFR and SCFSKP2, with an IC50 of 36 μM against Skp2-Cks1. NSC689857 can inhibit phosphorylation of p27 (IC50=30 μM). NSC689857 exhibits varying activity in different types of cancer, with higher resistance activity against leukemia cell lines compared to other cancer cells.

     NSC689857 Chemical Structure
  9. GC12712 NT157 IRS-1/2 inhibitor, inhibits IGF-1R and STAT3 signaling pathway NT157 Chemical Structure
  10. GC36783 NVP-BSK805 dihydrochloride A potent, selective JAK2 inhibitor NVP-BSK805 dihydrochloride Chemical Structure
  11. GC44491 O-Desmethyl Gefitinib O-Desmethyl gefitinib is the major metabolite of gefitinib in human plasma, formed by the cytochrome P450 isoform CYP2D6. O-Desmethyl Gefitinib Chemical Structure
  12. GC68321 O-Desmethyl gefitinib-d8 O-Desmethyl gefitinib-d8 Chemical Structure
  13. GC61627 Ochromycinone Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor. Ochromycinone Chemical Structure
  14. GC31677 Oclacitinib maleate (PF-03394197 maleate) Oclacitinib maleate (PF-03394197 maleate) (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) Chemical Structure
  15. GC15370 Olmutinib (HM61713, BI 1482694) Olmutinib (HM61713, BI 1482694) (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib (HM61713, BI 1482694) is used for NSCLC. Olmutinib (HM61713, BI 1482694) Chemical Structure
  16. GC64770 Oritinib Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively. Oritinib Chemical Structure
  17. GC17530 OSI-420 OSI-420 (OSI-420) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor. OSI-420 Chemical Structure
  18. GC36819 Osimertinib dimesylate Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. Osimertinib dimesylate Chemical Structure
  19. GC69635 OSM-SMI-10B

    OSM-SMI-10B is a derivative of OSM-SMI-10. Co-incubation of OSM-SMI-10B with Oncostatin M (OSM) significantly reduces STAT3 phosphorylation induced by OSM in cancer cells.

     OSM-SMI-10B Chemical Structure
  20. GC41329 Pacritinib FMS-like tyrosine kinase 3 (FLT3) and Janus kinase 2 (JAK2) are tyrosine kinases that mediate cytokine signaling and are frequently mutated in cancers, particularly acute myeloid leukemia. Pacritinib Chemical Structure
  21. GC66405 Panitumumab Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer. Panitumumab Chemical Structure
  22. GC66333 Panitumumab (anti-EGFR) Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer. Panitumumab (anti-EGFR) Chemical Structure
  23. GC69665 Patritumab

    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab has synergistic effects with Cetuximab and can effectively inhibit the phosphorylation of EGFR, HER2, HER3, ERK and AKT. Patritumab also induces apoptosis and inhibits the growth of pancreatic, non-small cell lung cancer and colorectal cancer xenograft tumors.

     Patritumab Chemical Structure
  24. GC15925 PD 158780 ErbB receptor family tyrosine kinase inhibitor PD 158780 Chemical Structure
  25. GC34105 PD153035 Hydrochloride (ZM 252868) A highly potent EGFR inhibitor PD153035 Hydrochloride (ZM 252868) Chemical Structure
  26. GC11015 PD168393 EGFR inhibitor PD168393 Chemical Structure
  27. GC10341 Peficitinb (ASP015K, JNJ-54781532) Peficitinb (ASP015K, JNJ-54781532) (ASP015K) is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. Peficitinb (ASP015K, JNJ-54781532) Chemical Structure
  28. GC17473 Pelitinib (EKB-569) Pelitinib (EKB-569) (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively. Pelitinib (EKB-569) Chemical Structure
  29. GC34210 Pertuzumab (Anti-Human HER2, Humanized Antibody)

    Pertuzumab (Anti-Human HER2, Humanized Antibody), the first of a new class of agents designated as HER dimerisation inhibitors, is a humanised IgG1 monoclonal antibody (mAb) that sterically binds domain II of the erbB2 receptor .

     Pertuzumab (Anti-Human HER2, Humanized Antibody) Chemical Structure
  30. GC69690 Petosemtamab

    Petosemtamab (MCLA 158) is a monoclonal antibody (mAb) that targets both EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab blocks EGFR signaling and receptor degradation in LGR5+ cancer cells. It can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc.

     Petosemtamab Chemical Structure
  31. GC14938 PF-03394197(Oclacitinib) Novel Janus kinase inhibitor PF-03394197(Oclacitinib) Chemical Structure
  32. GC36882 PF-06263276 PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. PF-06263276 Chemical Structure
  33. GC32927 PF-06459988 PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer. PF-06459988 Chemical Structure
  34. GC19288 PF-06651600 PF-06651600 (PF-06651600) is an orally active and selective JAK3 inhibitor with an IC50 of 33.1 nM. PF-06651600 Chemical Structure
  35. GC19405 PF-06700841 P-Tosylate Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. PF-06700841 P-Tosylate Chemical Structure
  36. GN10314 Picroside I Picroside I Chemical Structure
  37. GC19419 PIM inhibitor 1 phosphate Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. PIM inhibitor 1 phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines. PIM inhibitor 1 phosphate Chemical Structure
  38. GC36918 PIM-447 dihydrochloride A pan-Pim kinase inhibitor PIM-447 dihydrochloride Chemical Structure
  39. GC65278 PIM1-IN-1 PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC50 of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity. PIM1-IN-1 Chemical Structure
  40. GC19398 PIM447

    PIM447 is novel pan-PIM kinase inhibitor, including Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase.

     PIM447 Chemical Structure
  41. GC10643 Pimozide dopamine receptors inhibitor Pimozide Chemical Structure
  42. GC45756 Pimozide-d4 An internal standard for the quantification of pimozide Pimozide-d4 Chemical Structure
  43. GC40915 PKI-166 An inhibitor of EGFR PKI-166 Chemical Structure
  44. GC69728 Ponezumab

    Ponezumab (PF-04360365) is a humanized monoclonal antibody against amyloid beta protein of the IgG2 class. Ponezumab can reduce Aβ levels in the central nervous system and improve performance in various learning and memory models in mice. Ponezumab can be used for research on Alzheimer's disease.

     Ponezumab Chemical Structure
  45. GC64701 Povorcitinib Povorcitinib is a potent and selective inhibitor of JAK1. Povorcitinib Chemical Structure
  46. GC64700 Povorcitinib phosphate Povorcitinib phosphate Chemical Structure
  47. GC17916 Poziotinib A irreversible pan-HER inhibitor Poziotinib Chemical Structure
  48. GC30601 Propanamide Propanamide is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment. Propanamide Chemical Structure
  49. GC34742 Protosappanin A

    Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.

     Protosappanin A Chemical Structure
  50. GC69780 Pumecitinib

    Pumecitinib is a JAK inhibitor with anti-inflammatory activity.

     Pumecitinib Chemical Structure
  51. GC32733 Pyrotinib (SHR-1258) Pyrotinib (SHR-1258) (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively. Pyrotinib (SHR-1258) Chemical Structure
  52. GC32989 Pyrotinib dimaleate (SHR-1258 dimaleate) Pyrotinib dimaleate (SHR-1258 dimaleate) (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively. Pyrotinib dimaleate (SHR-1258 dimaleate) Chemical Structure
  53. GC65201 Quercetagetin Quercetagetin (6-Hydroxyquercetin) is a flavonoid. Quercetagetin Chemical Structure
  54. GC39081 Reticuline Reticuline shows anti-inflammatory effects through JAK2/STAT3 and NF-κB signaling pathways. Reticuline Chemical Structure
  55. GC12038 RG 13022 EGFR tyrosine kinase inhibitor RG 13022 Chemical Structure
  56. GC10217 RG-14620 inhibitor of epidermal growth factor (EGF) receptor kinase RG-14620 Chemical Structure
  57. GC37522 RGB-286638 A multi-kinase inhibitor RGB-286638 Chemical Structure
  58. GC37523 RGB-286638 free base A multi-kinase inhibitor RGB-286638 free base Chemical Structure
  59. GC25869 RO495 RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2). RO495 Chemical Structure
  60. GC16956 RO8191

    IFN-α receptor 2 agonist

     RO8191 Chemical Structure
  61. GC33061 Rociletinib hydrobromide (CO-1686 (hydrobromide)) Rociletinib hydrobromide (CO-1686 (hydrobromide)) (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. Rociletinib hydrobromide (CO-1686 (hydrobromide)) Chemical Structure
  62. GC37568 RTC-5 RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling. RTC-5 Chemical Structure
  63. GC69843 Ruserontinib

    Ruserontinib (SKLB1028) is an orally active inhibitor of EGFR, FLT3, and Abl kinases with an IC50 value of 55 nM against human FLT3. It has anti-tumor activity.

     Ruserontinib Chemical Structure
  64. GC37575 Ruxolitinib sulfate Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib sulfate Chemical Structure
  65. GN10164 Saikosaponin D Saikosaponin D Chemical Structure
  66. GC69854 Salviolone

    Salviolone is a natural diterpenoid derivative that can combat melanoma cells. Salviolone exhibits multifunctional effects on melanoma by blocking cell cycle progression, STAT3 signaling, and the malignant phenotype of A375 melanoma cells.

     Salviolone Chemical Structure
  67. GC19320 SAR-20347 SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively. SAR-20347 Chemical Structure
  68. GC25899 SC-1 SC-1 (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea, STAT3-IN-7), a Sorafenib analogue and potently inhibits the phosphorylation of STAT3, induces cell apoptosis through SHP-1 dependent STAT3 inactivation. SC-1 Chemical Structure
  69. GC61524 SC-43 SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects. SC-43 Chemical Structure
  70. GN10624 Scutellarin Scutellarin Chemical Structure
  71. GC44880 SD 1029 A JAK2 inhibitor SD 1029 Chemical Structure
  72. GC64774 SEL24-B489 SEL24-B489 is a potent, type I, orally active, dual PIM and FLT3-ITD inhibitor, with Kd values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively. SEL24-B489 Chemical Structure
  73. GC68430 Selatinib Selatinib Chemical Structure
  74. GC14658 SH-4-54 STAT inhibitor, potent SH-4-54 Chemical Structure
  75. GC32928 SH5-07 SH5-07 is a hydroxamic acid based Stat3 inhibitor with an IC50 of 3.9 μM in in vitro assay. SH5-07 Chemical Structure
  76. GC37651 SMI-16a A Pim-1 kinase inhibitor SMI-16a Chemical Structure
  77. GC19334 Solcitinib Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis. Solcitinib Chemical Structure
  78. GC17761 STA-21 A STAT3 inhibitor STA-21 Chemical Structure
  79. GC62559 Stafia-1 Stafia-1 is a potent STAT5a inhibitor (K i=10.9 μM, IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members. Stafia-1 Chemical Structure
  80. GC63203 Stafia-1-dipivaloyloxymethyl ester Stafia-1-dipivaloyloxymethyl ester (compound 27, 0-200 μM) decreases pSTAT5a expression significantly, and has no obvious inhibition on pSTAT5b. Stafia-1-dipivaloyloxymethyl ester Chemical Structure
  81. GC62254 Stafib-1 Stafib-1 is the first selective inhibitor of the STAT5b SH2 domain, with a Ki of 44 nM and an IC50 of 154 nM. Stafib-1 Chemical Structure
  82. GC63204 Stafib-2 Stafib-2 is a potent and selctive inhibitor of the transcription factor STAT5b, with an IC50 of 82 nM and 1.7 μM for STAT5b and STAT5a, respectively. Stafib-2 Chemical Structure
  83. GC52293 STAT3 Inhibitor 4m A STAT3 inhibitor STAT3 Inhibitor 4m Chemical Structure
  84. GC37688 STAT3-IN-1 STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis. STAT3-IN-1 Chemical Structure
  85. GC69952 STAT3-IN-11

    STAT3-IN-11 (7a) is a selective inhibitor of STAT3 that can inhibit the phosphorylation of the pTyr705 site on STAT3. It can also inhibit downstream genes (Survivin and Mcl-1) without affecting upstream tyrosine kinases (Src and JAK2) and p-STAT1 expression. STAT3-IN-11 can induce apoptosis in cancer cells, making it a promising candidate for the discovery of STAT3 inhibitors and anti-tumor agents.

     STAT3-IN-11 Chemical Structure
  86. GC69953 STAT3-IN-12

    STAT3-IN-12 is an effective STAT3 signaling inhibitor that can suppress the activation of the IL-6-induced JAK/STAT3 signaling pathway. It can inhibit cancer cell growth and migration, induce apoptosis (cell death), and block cell cycle progression. STAT3-IN-12 can be used in cancer-related research such as hepatocellular carcinoma (HCC) and esophageal cancer.

     STAT3-IN-12 Chemical Structure
  87. GC37689 STAT3-IN-3 STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3), with anti-proliferative activity. STAT3-IN-3 induces apoptosis in breast cancer cells. STAT3-IN-3 acts as a promising mitochondria-targeting STAT3 inhibitor for cancer research. STAT3-IN-3 Chemical Structure
  88. GC13647 STAT5 Inhibitor STAT5 Inhibitor is a STAT5 inhibitor with an IC50 of 47 μM for STAT5β isoform. STAT5 Inhibitor Chemical Structure
  89. GC65344 STAT5-IN-2 STAT5-IN-2 is a STAT5 inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect. STAT5-IN-2 Chemical Structure
  90. GC17886 Stattic

    Stattic is the first non-peptide small molecule inhibitor of STAT3, which effectively inhibits STAT3 activation and nuclear translocation.

     Stattic Chemical Structure
  91. GC67779 STX-0119 STX-0119 Chemical Structure
  92. GC11172 TAK-285 HER2/EGFR(HER1) inhibitor TAK-285 Chemical Structure
  93. GC32100 Tarloxotinib bromide (TH-4000) Tarloxotinib bromide (TH-4000) (TH-4000) is an irreversible EGFR/HER2 inhibitor. Tarloxotinib bromide (TH-4000) Chemical Structure
  94. GC65310 TAS0728 TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2 TAS0728 Chemical Structure
  95. GC32752 TAS6417 TAS6417 (CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM. TAS6417 Chemical Structure
  96. GC45004 TC 14012 (trifluoroacetate salt) C-X-C chemokine receptor type 4 (CXCR4) is a receptor for the stromal cell-derived factor-1 which is designated as chemokine ligand 12 (CXCL12). TC 14012 (trifluoroacetate salt) Chemical Structure
  97. GC11990 TCS-PIM-1-4a Pim inhibitor TCS-PIM-1-4a Chemical Structure
  98. GC41577 Tephrosin (synthetic) Tephrosin (synthetic) is a natural rotenoid which has potent antitumor activities. Tephrosin (synthetic) induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors. Tephrosin (synthetic) Chemical Structure
  99. GC31752 Tesevatinib (XL-647) Tesevatinib (XL-647) (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM. Tesevatinib (XL-647) Chemical Structure
  100. GC39022 Tetramethylcurcumin Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin Chemical Structure
  101. GC25992 TG-89 TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM. TG-89 Chemical Structure

Items 201 to 300 of 333 total

per page
  2. 1
  3. 2
  4. 3
  5. 4

Set Descending Direction